JPH0789806A - Method for thermally transpiring chemical agent - Google Patents

Abstract

PURPOSE:To provide a method for thermally transpiring a chemical agent, capable of arbitrarily setting the shape of a chemical agent-containing member, capable of freely setting the kind of the chemical agent and the transpiration amount of the chemical agent per unit time, and capable of uniformly heating the chemical agent-containing member, preventing the thermal decomposition of the chemical agent and the deterioration, e.g. clogging, of the chemical agent- containing member, and stably and effectively transpiring the chemical agent over a long period of time, and excellent in the effective trasnspiration rate. CONSTITUTION:When a chemical agent-containing member 1 containing the chemical agent is heated with a heat generator 12, a heat-conductive member 3 is installed between the chemical agent-containing member 1 and the heat generator 12 in a state in contact with or close to the heat generator, and the chemical agent-containing member is directly or indirectly heated through the heat-conductive member, i.e., with the heat transmitted through the heat- conductive member, to transpire the chemical agent.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for heat-evaporating a drug using a drug-containing body for heat-evaporation, and more specifically for the purpose of insecticidal, sterilizing, acaricidal, insect-proof, repellent, aroma, deodorant, etc. When heating the drug-containing body for heating and evaporation containing only the drug component or the drug together with the solvent and the additive with the heating element, the drug is indirectly heated through the heat conductive member, so that the drug can be used for a long period of time. The present invention relates to a heating evaporation method for stable and stable evaporation.

[0002]

2. Description of the Related Art Conventionally, as a heat-evaporative preparation, a method of heat-evaporating a solid, liquid or pasty medicine using a heating element has been known, and a typical example thereof is an electric mosquito trap. The electric mosquito repellent is an insecticidal mat containing a drug placed on a heating plate that is electrically heated to evaporate the drug and is used for insecticidal purposes. Further, a base material such as a fiberboard mainly composed of pulp or asbestos, which holds a chemical, is used.

In the heat evaporation method of this insecticidal mat represented by an electric mosquito trap, how to decompose the drug components and adjust the evaporation rate to stably evaporate the drug for a long time becomes a problem. . Therefore, various compounds have been conventionally known as sustained-release agents for stably evaporating a drug component over a long period of time. For example, piperonyl butoxide, butyl stearate and the like are actually used as sustained-release agents for pyrethroid insecticides, but the transpiration control of the drug is not sufficiently satisfactory. On the other hand, as a method for suppressing the decomposition of the active ingredient, it is generally known to blend an antioxidant, and Japanese Patent Application Laid-Open No. 53-121927 discloses various effective antioxidants. However, even if such a measure is taken, the residual rate of the active ingredient after heating and use is high, and a problem still remains in terms of sufficient effective use of the active ingredient. That is, in the conventional heating evaporation device, since the mat containing the drug is directly placed on the heating plate and heated, the entire mat is always kept in a higher temperature than necessary and is in contact with the heating plate. The active ingredient evaporates not only from the surface but also from the upper surface of the mat. Therefore, the amount of chemical vaporization in the early stage of heating is large, and after that, the amount of vaporization is significantly reduced
Stable transpiration cannot be obtained over a long period of time, the efficacy is reduced, and the residual rate of the drug is increased.

Further, when the temperature distribution of the heat generating plate is observed in detail, generally the surface temperature of the heat generating plate is not uniform, and there is a difference in surface temperature between the central part and the peripheral part. For example, the surface temperature of the central part of the heat generating plate is When the temperature is 170 ° C, the surface temperature of the peripheral portion is about 130 ° C. As a result, local heating of the central part of the mat occurs, which causes thermal decomposition of the active ingredient, and causes a decrease in drug evaporation efficiency and a decrease in efficacy. Further, in the conventional heat generating plate, since the surface temperature is not uniform as described above, the amount of chemical evaporation from the corresponding portion of the mat that contacts the central portion having a high surface temperature is large, and the concentration of the chemical in that portion is extremely dilute. . Therefore, most of the chemicals move to the central portion of the lower surface of the mat and evaporate. In this case, the chemicals need to move in the vertical and horizontal directions of the mat, and the moving distance becomes long, so that the chemical evaporation This is one of the factors that make it difficult to smoothly supply the drug and thus to stably evaporate the drug. Further, since the evaporation of the drug is concentrated in that portion, thermal decomposition of the drug is likely to occur, and a clogging phenomenon occurs, which hinders smooth evaporation of the drug thereafter.

As a measure for avoiding the above problems and obtaining stable drug evaporation over a long period of time, a part of the heating evaporator is immersed in the solution to absorb the solution into the heating evaporator. At the same time, various methods of heating and vaporizing the absorbed chemical liquid by heating the upper part thereof, so-called chemical liquid absorption type heat vaporization methods have been proposed. In such a chemical liquid absorption-type heat evaporation method, in order to heat the upper part of the heat evaporation body (liquid absorption core), a cylindrical heating element is surrounded by a space around the upper part of the liquid absorption core. It is installed like
1172). However, since the liquid absorbent core is indirectly heated by interposing air between the liquid absorbent core and the heating element, it slightly buffers the temperature distribution of the heating element itself, but the drug is located near the heating element, and it remains for a long time. When heated by heating, the drug is deteriorated in the heated portion above the liquid absorbent core, and a clogging phenomenon occurs due to accumulation over time, which tends to hinder the smooth evaporation of the drug near the end of evaporation. Also, the size of the absorbent core,
That is, since the surface area (heated area) of the chemical evaporation is limited by the shape of the heating element (diameter and length of the cylindrical heat radiating portion),
It has been practically difficult to increase the chemical vaporization area and to vaporize a large amount. Furthermore, in the case where a small amount of the drug is vaporized or the type of the drug is vaporized at a relatively low temperature, change the heating element temperature of the heating evaporation device or shorten the meshing distance between the heating element and the liquid absorption core to reduce the heated area. Had to be smaller. However, if the area to be heated is made small, the influence of the length of the liquid absorbent core and the temperature of the heating element on the amount of chemical evaporation will be great, and the yield will deteriorate considerably in order to guarantee the quality of the product. However, there was a limit to sharing the heating evaporation device. Even in the case of the above-described type in which the drug vaporizer is directly placed on the heat generating plate, the size of the drug vaporizer is limited by the shape of the heat generator.

[0006]

As described above, when an electrically heated heating element is used, it is very difficult to uniformly heat the drug vaporizer, and a temperature distribution is likely to occur. , The drug is severely deteriorated in the high temperature part, and the drug that deteriorates with time accumulates in the drug vaporizer, which adversely affects the drug evaporation, so that the desired drug effect cannot be obtained for a long period of time, and the efficacy is high. And the residual rate of the drug also increased. Further, the drug to be evaporated and the amount of drug evaporated per unit time are also limited by the heating element. Further, with respect to the evaporated drug, there is a problem that the drug is likely to adhere to the low temperature portion of the surface of the device for heating and evaporating, and the substantial amount of the drug is reduced. In general, when the evaporated drug comes into contact with an object having a low temperature (such as the wall of a device), the drug condensation phenomenon is likely to occur, which eventually lowers the effective evaporation rate of the drug, and the desired drug effect cannot be obtained.

Therefore, the object of the present invention is to solve the above-mentioned problems in the heat evaporation of the drug, to uniformly heat the drug-containing body, and to prevent the thermal decomposition of the drug and the deterioration of the drug-containing body such as clogging. However, it is an object of the present invention to provide a method for heating and evaporating a drug which can stably and effectively evaporate the drug over a long period of time and has an excellent effective evaporation rate. Furthermore, the object of the present invention is not limited by the shape of the heating element or the shape of the heating evaporation device, the shape of the drug-containing body can be arbitrarily set, and the kind of the drug and the amount of the drug evaporated per unit time can be freely set. It is to provide a heating evaporation method.

[0008]

In order to achieve the above object, according to the present invention, when a drug-containing body containing a drug is heated by a heating element, heat conduction between the drug-containing body and the heating element is achieved. A conductive member in contact with or close to a heating element, and directly or indirectly heats the drug-containing body through the heat conductive member, that is, by the heat transferred to the heat conductive member,
There is provided a method for heat evaporation of a drug, which comprises evaporating the drug. Therefore, according to the present invention, there is provided a method for evaporating a drug in the shape of the drug-containing body which is not restricted by the shape of the heat generating body serving as a heat source. According to one preferred embodiment of the present invention, a thermally conductive member and / or other protective member substantially surrounds the periphery of the drug-containing body, and when heated, it surrounds at least part of the surface of the drug-containing body. A space that communicates with the heat conductive member and / or the protection member is formed so that an upward heat flow from the lower side and / or the side direction is generated. In addition, the heat conductive member may be formed in a divided body, and each divided segment of the heat conductive member may be movable so as to be pressed against or contact with the heating element by elastic biasing force or gravity. . More preferably, the heat conductive member is formed in a vertically split cylindrical body.

[0009]

According to the method of heating and evaporating a drug of the present invention, the base material containing the drug, such as a conventional insecticidal mat, is heated directly on the surface of the base material in direct contact with the base material. Unlike the configuration described above, the drug-containing body is substantially indirectly heated by using a heat conductive member and, if necessary, another protective member. The heat conductive member is installed in contact with or close to the heat generating element, and the drug-containing body is heated via the heat conductive member to which the heat of the heat generating element is transferred. By the soaking section,
It becomes possible to heat more uniformly. Further, by covering the periphery of the drug-containing body with a heat conductive member and / or a protection member so that the drug-containing body can be heated not only on the heating body surface side but also on multiple surfaces, the drug-containing body can be covered. It becomes possible to take a large heating area. That is, by increasing the heated area of the drug-containing body, the need for local high-temperature heating is eliminated, and the temperature of the heated part of the drug-containing body is much lower than the maximum temperature of the surface of the heating element. Can be set to.

As a result, thermal decomposition of the drug during heating can be suppressed, deterioration of the evaporation surface of the drug-containing body such as clogging can be suppressed, and stable drug evaporation can be achieved for a long period of time with a high effective evaporation rate. Become. In addition, the drug-containing body is uniformly heated by the heat conductive member and / or the protective member and has a structure that produces a high heat retention effect, and the drug can be effectively evaporated. Further, when the drug-containing body is heated, the heat of the heat-generating body is transmitted through the heat conductive member, so that the shape and size of the drug-containing body can be arbitrarily set without being restricted by the shape of the heat-generating body. Since the amount of heat transferred from the body can be set arbitrarily, the type of drug and the amount of drug evaporated per unit time can be easily adjusted.

Further, in the constitution in which the periphery of the drug-containing body is roughly surrounded by the heat conductive member and / or the protection member,
By opening the lower side or side of the heat conductive member and / or the protective member and opening the drug evaporating port on the upper side to form a space communicating with the periphery of the drug-containing body, a heat rising airflow can be generated smoothly. , It is possible to effectively diffuse (evaporate) the evaporated drug. Moreover, due to the high heat retaining property of the heat conductive member and / or the protective member, it is possible to prevent the evaporated drug from adhering to the surface of the heating evaporation device, to prevent the device from being contaminated and to improve the effective evaporation rate of the drug. The desired drug evaporation effect can be maintained over a period of time. Moreover, since the drug-containing body is configured to be substantially surrounded by the heat conductive member and / or the protective member, it is possible to prevent the drug-containing body from being directly touched during use and storage, so that a child (infant) can Accidental ingestion or accidental ingestion of the drug-containing body can be prevented, and the child-proof property is improved. Also,
It is safe to handle because it does not need to touch the drug-containing body (medicine) directly with the container.
In particular, it is safe even for children with weak skin, and is also strong against impacts and the like, which is advantageous in terms of drug protection. Furthermore, the surface of the drug-containing body that is directly exposed to sunlight can be reduced, the light resistance during use and storage is improved, and the drug is prevented from being decomposed by light, resulting in a stable drug evaporation effect over a long period of time. Is obtained.

[0012]

DETAILED DESCRIPTION OF THE INVENTION As the heat conductive member which can be used in the present invention, any member can be used as long as it can transfer the amount of heat necessary for evaporation of the drug, and silver, copper, gold, aluminum, brass, tungsten, iron, nickel, cobalt. Examples include metals such as zinc, manganese, duralumin, stainless steel, brass, and ceramics such as aluminum oxide, silicon oxide, magnesium oxide, and barium oxide. Further, depending on the type of the medicine and the position where the medicine is installed on the heating element, the materials mentioned below as the protective member may be used as the heat conductive member. Further, the shape of the heat conductive member is arbitrarily set depending on the shape of the drug-containing body and the heating element of the heating evaporation device, but at least a part of the heat-conductive member is in contact with or close to the heating element to remove the drug-containing body. Any structure can be used as long as it can be indirectly heated. Further, in order to effectively use the heat from the heating element, it is possible to prevent the heat loss and improve the thermal efficiency by covering the surface of the heat conductive member with a heat insulating material or the like.

The material of the protective member used in the present invention is desired to have heat resistance and chemical resistance depending on the chemicals used. For example, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, polyacetal, melamine resin, polytetrafluoroethylene, phenol resin, unsaturated polyester resin, epoxy resin, urethane resin, methacrylic acid resin, polyarylate, Examples thereof include polyketone, polyamideimide, polyallyl sulfone, polyphenylene sulfide, polyphenyl sulfone, and polyether nitrile. In addition, a material obtained by kneading a metal powder of aluminum or the like or vapor-depositing a metal can also be used.

The method of heating and evaporating via the heat conductive member of the present invention is a method in which the drug-containing body is placed on a heating plate to evaporate the drug, or a part of the heat-evaporator is immersed in a chemical solution. It is possible to apply the method of evaporating the chemical solution by absorbing the chemical solution and heating the upper part thereof, and moreover, regardless of these methods, it is possible to use heating elements of various shapes. is there. Speaking of a more preferable evaporation method of the heating evaporation method of the present invention, only the drug, or a drug-containing body containing the drug together with the minimum necessary solvent and additives, the heat-generating body as a heat source, heat conductivity A method of uniformly heating through a member may be mentioned, but the shape of the heating element at this time is not limited as described above.

In this way, it is possible to evaporate a high-concentration drug containing only the drug component or the minimum necessary solvent.
It is more preferable because it has better thermal efficiency than the conventional chemical vapor absorption type heating evaporation method. That is, in the case of the chemical liquid absorption type, not only the evaporation of the drug but also the evaporation of the solvent is required, so unnecessary heat is used, and it takes time to reach the amount of evaporation to obtain the desired effect. On the other hand, in the method of evaporating the drug only with the drug or with the minimum solvent, the heat is required only for the evaporation of the drug, so that the thermal efficiency is very good, and the drug can be evaporated with a smaller amount of heat, and the heat generation is reduced. The power consumption of the body is low, and it is possible to save energy, and the drug-containing body is quickly heated immediately after the heating element is energized, and the rise of drug evaporation becomes very good. For example, in the case of heating and evaporating an insecticide, , A stable insecticidal effect is obtained from the beginning of use. In addition, since the solvent is not used unnecessarily, liquid leakage does not occur, and a very compact design is possible, and even when only the drug component or the solvent is used, it is used only at the minimum necessary. In the sense that it is possible to significantly reduce the adverse effect on the atmosphere due to evaporation of the solvent.

In the heat evaporation method of the present invention, the drug-containing body for heat evaporation that is preferably used is obtained by impregnating or coating a drug with an inorganic powder and / or an organic powder as a base material. As calcium hydrogen phosphate and its anhydride, calcium phosphate, calcium phosphate-based apatite, magnesium metasilicate aluminate, hydrotalside, aluminum hydroxide gel, alumina hydroxide magnesium, calcium carbonate, aluminum silicate, magnesium silicate, anhydrous silicic acid Inorganic powder such as clay, diatomaceous earth, kaolin, colloidal silica, water glass, aluminum phosphate, magnesium phosphate, gypsum, magnesia cement, tungsten, zinc oxide, red iron oxide, tungsten trioxide, zirconium oxide, and PT.
Fluorine-based resins such as FE (tetrafluoroethylene resin) and PVdF (vinylidene fluoride resin), polyacetal, polyarylate, polyethylene ether ketone, polyethylene, polyethylene terephthalate, polycarbonate,
Nylon 6, Nylon 66, Nylon 11, Nylon 1
2. Polyamides such as aromatic nylon and copolymers thereof, polyimides, polyamideimides, polysulfone resins such as polysulfone / polyethersulfone, polyphenylene ether, polyphenylene sulfide, polybutylene terephthalate, polypropylene, polymethyl Penten, AES resin, AS resin, ABS resin, MBS resin, crystalline cellulose, CMC, MC, starch, HPMC,
Organic powders such as HPC and HPS are exemplified. The drug-containing body for heat evaporation is a mixture of inorganic powder and / or organic powder,
It can be prepared by methods such as compression molding and extrusion molding, but the molding method is not particularly limited.
The shape of the drug-containing body for heat evaporation of the present invention is arbitrary such as flat plate, donut shape, and columnar shape.

Among the organic powders, particularly when a thermoplastic resin powder is used, the strength of the drug-containing body is improved by molding the drug-containing body and then heat-sealing it near the melting point of the thermoplastic resin powder. You can also That is, by melting the contact portion of the thermoplastic resin powder in close contact with the inorganic powder and / or the organic powder, the strength against breakage and cracking can be obtained without losing the porosity. Furthermore, since the thermoplastic resin powder has excellent water resistance and moisture resistance, it does not exhibit strength reduction even at high humidity.
It is possible to mold a drug-containing body for heat vaporization of stable quality which maintains a constant strength even under an environment of general use. Further, since the thermoplastic resin powder is stable to water, by using the chemical substance for heat evaporation of the present invention, water-based deodorant, antibacterial and fungicide, insecticide, fragrance, etc. It is possible to evaporate the liquid medicine and the emulsified drug solution.

In addition, the drug substance for heat evaporation of the present invention contains the fluidity and lubricity of powder during compression molding and extrusion molding.
In order to improve the lubricity, if necessary, as a lubricant and a lubricant within a range that does not impair the characteristics of the agent containing heat for evaporation,
Talc, stearates such as magnesium stearate and sodium stearate, amino acid lubricants such as N-lauryl-DL-aspartic acid-β-lauryl ester and N ⁶ -lauroyl-L-lysine, boric acid, liquid paraffin It is also possible to add waxes such as sodium benzoate and carbowax. Further, fibrous powder such as glass fiber or carbon fiber may be added to improve the strength of the drug-containing body for heat evaporation.

If necessary, pigments, dyes, preservatives, antioxidants, ultraviolet absorbers, flame retardants, and accidental food inhibitors are added to the heat-transpiration agent-containing body as long as its characteristics are not impaired. You may mix | blend an agent. As an antioxidant that can be blended, stearyl-β- (3,5-di-t-butyl-4
-Hydroxyphenyl) propionate, 2,2'-methylenebis (4-methyl-6-t-butylphenol), 2,2'-methylenebis (4-ethyl-6-t-)
Butylphenol), 4,4'-methylenebis (2,6
-Di-t-butylphenol), 4,4'-butylidenebis (3-methyl-6-t-butylphenol), 4,
4'-thiobis (3-methyl-6-t-butylphenol), 1,3,5-trimethyl-2,4,6-tris (3,5-di-t-butyl-4-hydroxybenzyl)
Benzene, 1,1,3-tris- (2-methyl-4-hydroxy-5-t-butylphenyl) butane, tetrakis- [methylene-3- (3 ', 5'-di-t-butyl-
4'-hydroxyphenyl) propionate] methane,
2-mercaptobenzimidazole, 1,1-bis (4
-Hydroxyphenyl) cyclohexane, N-phenyl-β-naphthylamine, N, N'-diphenyl-p-phenylenediamine, 2,2,4-trimethyl-1,2-
Dihydroquinoline polymer, 6-ethoxy-2,2,4
-Trimethyl-1,2-dihydroquinoline, 2-t-butyl-6- (3-t-butyl-2-hydroxy-5-methylbenzyl) -4-methylphenyl acrylate,
3,5-di-t-butyl-4-hydroxy-benzylphosphonate-diethyl ester, bis (3,5-di-t-butyl-4-hydroxybenzylphosphonate ethyl) calcium, tris [2- (3 ', 5'-di-t-
Butyl-4'-hydroxyhydro-cinnamoyloxyl) ethyl] isocyanurate, tris- (4-t-butyl-2,6-di-methyl-3-hydroxybenzyl)
Isocyanurate, 3,9-bis [1,1-di-methyl-2- {β- (3-t-butyl-4-hydroxy-5-
Methylphenyl) propionyloxy} ethyl] -2,
4,8,10-tetraoxaspiro [5.5] undecane, ditridecyl-3,3'-thiodipropionate,
Dimyristyl-3,3'-thiodipropionate, distearyl-3,3'-thiodipropionate, triethylene glycol-bis [3- (3-t-butyl-5-methyl-4-hydroxyphenyl) propionate ],
1,6-hexanediol-bis [3- (3,5-di-
t-Butyl-4-hydroxyphenyl) propionate], N, N′-hexamethylenebis (3,5-di-t
-Butyl-4-hydroxy-hydrocinnamamide),
2,2-thio-diethylenebis [3- (3,5-di-t
-Butyl-4-hydroxyphenyl) propionate], N, N'-bis [3- (3,5-di-t-butyl-4-hydroxyphenyl) propionyl] hydrazine, tris- (3,5-di-t -Butyl-4-hydroxybenzyl) -isocyanurate, 2,4-bis- (n
Examples thereof include compounds such as -octylthio) -6- (4-hydroxy-3,5-di-t-butylanilino) -1,3,5-triazine. These may be used alone or in combination of two or more. By adding these antioxidants, effects such as prevention of thermal deterioration during heating, prevention of oxidation, decomposition of chemicals, prevention of polymerization, and improvement of long-term stability over time can be obtained.

Further, antioxidants generally called peroxide decomposers, such as dilauryl thiodipropionate (DLTP) and distearyl thiodipropionate (D
STP) and the like may be used in combination with the antioxidant. Further, by using an ultraviolet absorber as a stabilizer, the light resistance during storage and use can be further improved.

The heating temperature of the heating and vaporizing method of the present invention is selected depending on the drug to be contained, but it is usually preferable to maintain the surface temperature of the heated portion of the drug-containing body for heating and vaporizing at 40 ° C to 200 ° C. . In addition, as a heat generation method of the heating element, a resistance heater (nichrome wire or the like), semiconductor (PTC)
A method of energizing a heater using, oxidation reaction (oxidation of metals such as iron and magnesium), hydrolysis reaction (reaction of quicklime and water, etc.), combustion heat of alcohol, gas, kerosene, wax, etc., and platinum catalyst A method of utilizing the combustion heat of the used alcohol or gas, a method of directly or indirectly utilizing other heat source, or the like is used.

The heat-evaporative drug-containing body of the present invention may contain various evaporative drugs depending on the purpose of use. For example, when used for the purpose of insecticidal, as the insecticide, it is possible to use various transpiration insecticides that have been conventionally used, such as pyrethroid insecticides, carbamate insecticides, organophosphorus insecticides and the like. You can Generally, a pyrethroid insecticide is preferably used because it is highly safe, and examples thereof include allethrin, d1 · d-T80-allethrin, d · d-T80-allethrin, and d · d-T8.
Various conventionally known pyrethroid insecticides such as 0-praletrin, phthalthrin, d-T80-resmethrin, d-T80-flamethrin, permethrin, phenothrin, fenvalerate, cypermethrin, cifenotrin, empentrin, terrarethrin, etofenprox, benfluthrin and the like. Can be used. Similarly, when used for the purpose of aroma, various natural and artificial flavors can be used, for example, animal or plant natural flavors, hydrocarbons, alcohols, phenols, aldehydes, ketones, lactones, oxides. , Artificial flavors such as esters, etc., and one of these can be used alone,
It is also possible to use a mixture of two or more kinds. Furthermore, various chemicals such as deodorants, germicides, antibacterial agents, rust preventives, acaricides, and repellents can be used depending on the purpose, as long as they can be evaporated by heating.

Then, at the time of incorporating the drug into the drug substance for heat evaporation, the minimum necessary solvent can be used for the purpose of improving the permeability or diffusibility of the drug. An aliphatic saturated hydrocarbon solvent can be used as the solvent. Examples of commercially available products include No. 0 solvent H (manufactured by Nippon Oil Co., Ltd.), No. 0 solvent M (manufactured by Nippon Oil Co., Ltd.), normal paraffin (Mitsuishi / Texaco Chemical Co., Ltd.), IP solvent 2028 (made by Idemitsu Petrochemical Co., Ltd.) and the like. Moreover, an unsaturated aliphatic hydrocarbon solvent can also be used. In addition, water, alcohols, glycol ethers such as ethylene glycol monobutyl ether, glycols, and esters such as IPM can be used.

Hereinafter, various aspects of the heat evaporation method of the present invention will be specifically described. FIG. 1 shows a specific example of the heating evaporation method of the present invention. In the figure, 1 is a drug-containing body, and 2
Is a container including a disc-shaped heat conductive member 3 and a cap-shaped protection member 9. A plurality of pedestal portions 4 are integrally formed on the outer peripheral surface of the disc-shaped heat conductive member 3, and convex portions 5 and 6 are provided on the upper and lower surfaces thereof at a plurality of locations. The outer peripheral surface of the drug-containing body 1 is slidably fitted onto the inner surface of the pedestal portion 4 of the heat conductive member 3, and is placed on the convex portion 5 on the upper surface of the heat conductive member 3, and the cap-shaped protection member 9 is provided. Is fitted and fixed to the engaging stepped portion 7 on the outer surface of the pedestal portion 4, and the container 2 is assembled. Other arbitrary methods can be used to fix the heat conductive member 3 and the protection member 9. A plurality of pedestals 4 of the heat conductive member 3 are provided at the bottom of the container 2.
The air gap 8 is formed by the space between them, and the evaporation port 10 is formed in the center of the upper surface of the cap-shaped protection member 9. Therefore, in the container 2 composed of the heat-conductive member 3 surrounding the drug-containing body 1 and the protective member 9, there is a space communicating from the lower vent hole 8 to the upper evaporation port 10 through the periphery of the drug-containing body 1. It is formed.

The container 2 containing the drug-containing body 1 assembled as described above is placed on the plate-shaped heating element 12 provided in the heating evaporation device 11, and the heating element 12 is heated for use. To do. Due to the heat generated by the heating element 12, the heat conductive member 3 receives heat conduction directly (via the convex portion 6 on the lower surface) or indirectly, and the internal temperature of the container 2 rises. As this temperature rises, as shown by the arrow in the figure, a heat rising airflow is generated from the ventilation port 8 through the periphery of the drug-containing body 1 to the evaporation port 10,
Further, the drug evaporates from the drug-containing body 1 that is uniformly heated over the entire surface, and smoothly evaporates / diffuses from the evaporation port 10 by riding on the above-mentioned heat rising airflow. The protection member 9 protects the drug-containing body 1 and also functions as a heat retaining material during heating. Therefore, the container itself has high heat retention,
It prevents the once evaporated drug from adhering to the periphery of the evaporation port 10. The bottom of the heating evaporation device 11 and the heating element 12
Vents 13 and 14 are also formed in the periphery, and the heating element 1
Along with the heat generation of 2, a heat rising airflow that flows through the heating evaporation device 11 as shown by the arrow in the figure is also generated, and this heat rising airflow promotes the diffusion of the drug evaporated from the drug-containing body 1. Also, it contributes to the prevention of adhesion of the evaporated chemicals around the evaporation port 10.

FIG. 2 shows a modification of the configuration shown in FIG.
Illustration of the heating evaporation device is omitted. In this modified example, a ring-shaped drug containing body 1a is used, which is
The heat conductive member 3a is arranged around a cylindrical body 16 integrally projecting upward from the central hole 15 of the heat conductive member 3a. Further, a plurality of slit-shaped ventilation holes 8a are formed on the peripheral wall of the cap-shaped protection member 9a, and the evaporation holes 10 are formed at a plurality of positions on the upper wall.
a is formed. Therefore, in the case of the configuration shown in FIG.
As the internal temperature of the container 2a rises due to the heat generation of the heat generating body 12, as shown by the arrow in the figure, a heat rising airflow is generated from the ventilation hole 8a to the evaporation port 10a through the periphery of the drug-containing body 1a and heat generation. From the gap between the body 12 and the heat conductive member 3a, through the central hole 15 in the tubular body 16, the evaporation port 10
A heat rising airflow toward a is also generated, and the evaporation and diffusion of the drug can be performed more smoothly.

FIG. 3 shows an example of the configuration when a small block-shaped heating element is used. In this configuration example, a lumpy drug-containing body 1b is used, and the container 2b has a bottom plate portion 3b and a bottom plate portion 3b each having a concave portion 18 for mounting the drug-containing body 1b in the center of the upper surface. And a cap portion 17 having a hemispherical shape that is capped on the bottom plate portion 3b and the cap portion 17 are both made of a heat conductive member. Further, the peripheral edge of the bottom plate portion 3b is cut out at a plurality of positions to form the vent hole 8b, and the cylindrical body 19 is formed from the center portion of the lower surface thereof.
And the block-shaped heating element 12b is disposed inside the cylindrical body 19. Therefore, in the case of the configuration shown in FIG. 3, the bulk drug-containing body 1b has a container 2 whose substantially entire circumferential surface is a heat conductive member.
It is heated by b, and more uniform heating is performed, and
It also has an excellent heat retention effect.

FIG. 4 shows an example of mounting on a heating evaporation device equipped with a heating element having an annular or semi-annular radiator. In this configuration example, the heat conductive member 3c has the upper portion 2
0 is a funnel shape and the lower part 21 is formed in a cylindrical shape, and a plurality of protrusions 2 are formed on the inner peripheral surface of the connecting portion of the funnel shape part 20 and the cylindrical part 21.
2 is provided so as to project, and the drug-containing body 1c is mounted on the projecting portion 22. On the other hand, the container 2c is composed of a container-shaped protection member 9c having a central hole 23 having a size into which the cylindrical portion 21 can be inserted, and the protection member 9c is vertically arranged at the engagement step 7c. It has a structure that can be divided. The funnel-shaped portion 20 of the heat conductive member 3c is the container 2c.
On the other hand, a ring-shaped heating element 12c is arranged around the cylindrical portion 21 below the inside. In the case of the configuration shown in FIG. 4, when the heat from the heating element 12c is transferred to the heat conductive member 3c, the drug-containing body 1c has a funnel-shaped portion 20 around it.
Is heated uniformly, and as the temperature inside the container rises, as shown by the arrow in the figure, the cylindrical portion 21 of the heat conductive member 3c is removed from the vent hole 24 formed in the center of the bottom of the heating evaporation device 11c. A heat rising airflow that passes through the periphery of the drug containing body 1c toward the evaporation port 10c in the upper part of the container 2c is generated, and the drug evaporated from the drug containing body 1c rides on the heat rising airflow and smoothly diffuses from the evaporation port 10c. Also in this case, the container 2c including the protection member 9c protects the drug-containing body 1c and also functions as a heat retaining material during heating. Therefore, the container itself has a high heat retaining property and prevents the once evaporated drug from adhering to the periphery of the evaporation port 10c.

FIGS. 5 and 6 show an example in which a heating element having a heater eccentric ring-shaped heat radiation portion is used, and the heat conductive member has a movable split structure. That is, the heat conductive member 3d has a structure in which the divided segments 25a and 25b, which are vertically divided into two, constitute a tubular body having an upper small diameter portion and a lower large diameter portion as a whole. , 25b are formed as inclined surfaces 26 so that a cutout portion that expands toward the upper end surface is formed. A taper 27 is attached to the outer surface of the upper end of each of the divided segments 25a and 25b. The heat-conducting member 3d having such a movable two-division structure is attached to the heating element 12d.
When mounted on the ring-shaped heat radiation tube 28, the heating elements 12d are tapered because the outer surfaces of the upper ends of the two divided segments 25a and 25b are easily inserted.
It can be easily inserted into the ring-shaped heat dissipation cylinder 28.
At the time of insertion, the upper small diameter portions of the divided segments 25a and 25b slide on the inner peripheral edge of the lower end of the ring-shaped heat radiation cylinder 28, and when a lateral force is applied above the fulcrum S, the divided segments 25a and 25b fall inward. Therefore, it is easily inserted into the ring-shaped heat dissipation cylinder 28. When the insertion is further advanced, a lateral force is applied by the lower edge of the heating element below the fulcrum S to the widened portion of the lower portion of the upper small diameter portion of the divided segments 25a and 25b, so that the segment is upright. Return to the original state, both split segments 25
The outer surfaces of the upper small-diameter portions of a and 25b come into contact with the inner surface of the ring-shaped heat dissipation cylinder 28, and efficient heat conduction is performed.

Note that depending on the shape of the divided segments of the heat conductive member, when each divided segment is placed alone on a horizontal plane, tilting occurs depending on the position of the center of gravity of the divided segment itself, but the center of gravity is shown in FIG. When it is in the upright position or is tilted outward (indicated by the hollow arrow in the figure), it is tilted inward when it is inserted into the ring-shaped heat radiation tube of the heating element in the same manner as described above, but gravity after insertion. Stops at the most stable position, resulting in the segment 25a '
The outer surface of the upper small-diameter portion of the other segment (not shown) comes into contact with the inner surface of the ring-shaped heat radiating cylinder of the heating element (even if the center of gravity is tilted outward, it can be maintained by the container 2d). Further, the central portions of the two divided segments 25a and 25b are pivotally connected by a suitable connecting means (not shown) such as a pin, and the both divided segments 25a are connected by a suitable biasing means (not shown) such as a spring. , 25b, the upper small diameter portion may be urged to expand.
Also in the case of such a thermally conductive member having a movable two-divided structure, since the outer surfaces of the upper ends of the two divided segments 25a and 25b are provided with the taper 27, the biasing force in the direction of expanding the two is increased. It can be easily pushed into the ring-shaped heat dissipation cylinder 28 against resistance, and once mounted, it is elastically biased to both the divided segments 25a, 25b of the heat conductive member 3d.
The upper small diameter portion of the heating element is urged in the expanding direction, and the heating element 12d
It is pressed against the inner surface of the ring-shaped heat radiating cylinder 28 to enable more efficient heat conduction.

On the other hand, the container 2d is composed of a container-shaped protection member 9d having a tubular portion 30 projecting inwardly at the center of the bottom plate 29, and the protection member 9d is vertically arranged at the engagement step portion 7d. It has a structure that can be divided. In the container 2d, the drug-containing body 1d is placed on the upper end surface of the tubular portion 30, and the heat conductive member 3d having the movable two-division structure is housed so as to surround the drug-containing body 1d. . Further, an indicator function member 31 is fitted in the cylindrical portion 30 of the container 2d, the indicator function member 31 having an indicator function that functions in accordance with the end of the evaporation of the drug and notifies the end of the evaporation of the drug. As such an indicator function member 31,
Various materials that change the color tone by heating can be used. For example, an electron-donating color-developing organic compound that exhibits a color tone change over time with heating, a material containing a dye that causes a color tone change by evaporation or sublimation, a sublimation agent, and the like can be used. Also, anthraquinone oil-soluble dyes,
Transferring dyes such as monoazo-based oil-soluble dyes, disazo-based oil-based dyes, triallylmethane-based oil-based dyes, naphthalimide-based oil-based dyes, anthraquinone-based disperse dyes, and basic dyes that migrate in polymeric substances over time with heating Using a material contained therein, a synthetic resin is used for the bottom plate 29 of the container 2d, and the transferable dye is transferred to the bottom plate 29 of the container 2d with heating with time, and the indicator function is exhibited by the color tone change of the bottom plate 29. It can also be configured. As described above, the container 2d in which the drug-containing body 1d and the thermally conductive member 3d having the movable two-divided structure are housed is placed in the inward recessed portion formed in the middle plate portion 33 of the dome-shaped heating evaporation device 32. The upper small diameter portion of the heat conductive member 3d is mounted in the ring-shaped heat radiation cylinder 28 of the heating element 12d as described above. As a method of mounting the container 2d and the middle plate portion 33 of the heating evaporation device 32, any method such as screwing or snap fitting can be adopted.

In the case of the configuration shown in FIGS. 5 and 6, the heating element 1
As the internal temperature of the container 2d rises due to the heat generated by 2d, the heat rises from the vent hole 8d formed in the bottom plate 29 of the container 2d to the evaporation port 10d through the periphery of the drug-containing body 1d as shown by the arrow in the figure. An airflow is generated, and a heat rising airflow is also generated from the ventilation hole 34 formed in the bottom portion of the peripheral wall of the heating evaporation device 32 to the evaporation hole 10d through the ventilation hole 35 formed in the middle plate part 33. In addition to being able to diffuse more smoothly, the drug-containing body 1d is heated almost uniformly on its entire peripheral surface by the heat conductive member 3d to perform more uniform heating, and these are contained in the container 2d composed of the protection member 9d. Since it is housed in, it has an excellent heat retention effect. Further, the elapsed time of use, the end point, or the expiration of the use period can be displayed by the indicator function member 31 with the progress of the evaporation of the drug. Further, by using the heat conductive member having the movable two-divided structure as in the above-mentioned configuration example, advantages such as improvement of the attachment property to the heating evaporation device (heating element) and improvement of heat conduction efficiency can be obtained. In particular, when the heat conductive member is inserted into the ring-shaped heat dissipation tube as shown in FIG. 6, when the heat conductive member is a single member, or when a plurality of members are fixed, the ring can be attached due to their mountability. It is necessary to configure the heat conductive member with a diameter smaller than that of the heat dissipation tube, and it is difficult to closely contact the heat generating member and the heat conductive member.
On the other hand, by adopting a movable split structure as shown in FIG. 5 and FIG. 6, the heat conductive member is improved in mountability, and the heat conductive member is moved to a predetermined position so that the ring-shaped heat dissipation tube is moved. , Or when the divided segments are connected to each other via spring means or the like, a part of the heat conductive member is urged toward the heat generating element at the end of the attachment and is pressed against the heat generating element. As a matter of course, the heat conduction efficiency is improved by directly contacting the heat generating member and the heat conductive member, rather than by interposing the space therebetween.

FIG. 8 shows an example in which a cylindrical drug-containing body and a cylindrical heat conductive member are used. That is, the heat conductive member 3e is formed in a cylindrical shape with upper and lower ends opened, and a plurality of projecting locking portions 36 are projectingly provided on the inner peripheral surface of the lower end thereof, so that the cylindrical drug-containing body 1e is projected. It is arranged in the cylindrical heat conductive member 3e in a state of being supported by the cylindrical locking portion 36. Further, the cylindrical heat conductive member 3e is fitted into the hole of the engaging portion 37 formed at the center of the upper portion of the cap-shaped protection member 9e. A plurality of projections 38 and grooves 39 having a predetermined length are intermittently formed along the circumferential direction on the upper outer peripheral surface of the cap-shaped protection member 9e. Similarly, the container of the lower vessel 41 of the heating evaporation device 40 is formed. Similar protrusions 43 and grooves (not shown) are also formed on the inner peripheral surface of the lower end portion of the storage portion 42. In assembling the cap-shaped protection member 9e fitted with the cylindrical heat-conductive member 3e for accommodating the drug-containing body 1e into the heat evaporation device 40, first, the cap-shaped protection member 9e is formed on the upper outer peripheral surface of the cap-shaped protection member 9e. The notched portions of the protruding portion 38 and the groove portion 39 are aligned with the protruding portion 43 formed on the inner peripheral surface of the lower end portion of the container accommodating portion 42 of the lower body 41, and are inserted from below. Next, the cylindrical heat conductive member 3e is placed in the annular heating element 12e placed on the plurality of pedestal portions 44 projectingly provided on the upper surface of the container housing portion 42.
With the upper end of the cap inserted, the cap-shaped protection member 9e
When the cap-shaped protection member 9e and the container housing portion 42 are fitted and fitted with each other by slightly rotating the cap-shaped protection member 9e, the cap-shaped protection member is formed by the notches between the projections and the groove portions. A ventilation hole 46 is formed between 9e and the container storage 42.

In the case of the structure shown in FIG. 8, as the internal temperature rises due to the heat generated by the heating element 12e, the vent hole formed in the lower part of the lower body 41 of the heating evaporation device 40 as shown by the arrow in the drawing. A heat rising airflow is generated from 48 toward the transpiration port 10e formed in the central portion of the top surface of the upper body 45 through the gap between the drug-containing body 1e and the cylindrical heat conductive member 3e, and the vent hole is also generated. A heat rising airflow from 46 and 47 through the gap between the heating element 12e and the heat conductive member 3e toward the transpiration port 10e and a heat rising airflow from the vent 49 through the periphery of the heating element 12e to the transpiration port 10e are also generated. The chemicals can be evaporated and diffused more smoothly. In addition, since the cylindrical drug-containing body 1e is heated by the cylindrical heat conductive member 3e on the entire peripheral surface thereof, more uniform heating is performed and the heat retaining effect is excellent. The configuration examples described above are some specific examples of the heating evaporation method of the present invention,
It goes without saying that the present invention is not limited to these, and the structures and configurations of various heating evaporation devices, drug-containing bodies and containers are arbitrary, and various forms can be used.

[0035]

EXAMPLES The present invention will be described more specifically below with reference to Examples and Comparative Examples. Example 1 Each of a heat-resistant plastic plate (made of polyphenylsulfone), a copper plate, and an aluminum plate (24 × each) was placed on a plate-shaped heating element using a positive temperature coefficient thermistor of a commercially available heating evaporation device.
36 mm, thickness 1 mm) was placed on each plate, and the surface temperature of the upper surface of each plate was measured with a thermocouple type surface thermometer. The surface temperature of the heating element was also measured in the same manner. In addition, the temperature measuring unit has five points (see FIG. 9) that divide the diagonal line of each plate or heating element into six equal parts.
Measurement) under the condition of room temperature of 25 ° C. The measurement results are shown in Table 1 and FIG.

[0036]

[Table 1]

Example 2 A heat-resistant plastic plate (made of polyphenylene ether), a copper plate, and an aluminum plate 51 were placed on a plate-shaped heating element 50 using a positive temperature coefficient thermistor of a commercially available heating evaporation device.
(60 × 36 mm each, thickness 1 mm) is shown in FIG.
Installed as shown in Fig. 1, and further placing a commercially available mosquito repellent mat 52 on the upper surface of each plate 51 opposite to the heating element 50, heat vaporization is performed, and the voluntary insecticidal active ingredient is sucked every 3 hours. And collected on silica gel and repeated for 12 hours, and a sample solution extracted with acetone for each was quantitatively analyzed by gas chromatography. Next, the drug-containing body after heat evaporation for 12 hours was extracted with acetone, and the active ingredient was quantitatively analyzed in the same manner. In addition, d.d-T80-praletrin was used as the insecticidal active ingredient. The results of each are shown in Table 2.

[Table 2]

As is clear from the results shown in Table 1 and FIG. 10, the temperature distribution on the upper surface of the heating element is highest at the central portion of the heating element and lowers toward the ends. The temperature difference between the maximum temperature and the minimum temperature of the upper surface of the heating element is about 40 ° C. or higher. When a plate made of polyphenylsulfone, which has a relatively low thermal conductivity, is placed on the heating element, the on-board temperature is generally lower than the heating element surface temperature, and the temperature difference between the maximum temperature and the minimum temperature is also Although it was somewhat relaxed, it was thought that a considerable thickness was required to eliminate the temperature difference, heat loss was large, and it was unsuitable for evaporating the chemicals of a commercially available mosquito repellent mat. However, in the case of a copper plate and an aluminum plate (thickness 1 mm) having good thermal conductivity, the temperature difference was alleviated and a substantially uniform temperature distribution was obtained. Furthermore, the temperature is not entirely lowered, and the temperature of the portion located at the highest temperature portion of the heating element surface is lowered, and the temperature of the low temperature portion is raised, resulting in an overall uniform temperature. ing. Therefore, the amount of heat is sufficient to evaporate the drug on the commercially available mosquito repellent mat, and by installing the heat conductive member on the upper surface of the heating element, the drug-containing body can be uniformly heated and the heat loss is reduced. It is also very effective in evaporating the drug.

Next, as is clear from the results shown in Table 2, the heat conductive member was made larger than in the first embodiment, and the drug (d.d-T80-praletrin) was placed at a position apart from the heating element plate. 2) is evaporated, the plate made of polyphenylene ether does not evaporate the drug at any time, and the heat from the heating element is not effectively used. On the other hand, when a member with high thermal conductivity (copper plate, aluminum plate) was used, the desired effective chemical evaporation was obtained.
Furthermore, compared with the case where the mosquito repellent mat is placed directly on the heating element, the decrease in the amount of drug evaporated in the latter half of use is suppressed, and the amount of drug evaporated tends to be maintained for a relatively long time. The estimated unrecovered rate of the drug was also low. It is presumed that this is because the temperature distribution on the heating surface was uniform and the heating surface was not subjected to local heating, so that the decomposition of the drug was suppressed. Moreover, by using the heat conductive member, it is possible to evaporate the drug at any place regardless of the shape and the place of the heating element.

Example 3 An anhydrous calcium hydrogen phosphate (89.8 w / w%), nylon 12 was used in the chemical vaporization apparatus having the structure shown in FIG.
(5.0 w / w%), crystalline cellulose (4.0 w / w
%), Magnesium stearate (1.0 w / w%),
On a substrate consisting of stearyl-β- (3,5-di-t-butyl-4-hydroxyphenyl) propionate (0.2 w / w%), a heat transpiration insecticide (d · d-T80-praletrin) 310 mg A cylindrical drug-containing body 1e in which is contained by dipping is fitted into the cap-shaped protection member 9e in a state of being arranged in the cylindrical heat-conductive member 3e, and The upper end portion was placed in the ring-shaped heating element 12e and heated to evaporate the insecticide.

Comparative Example 1 As shown in FIG. 12, a cylindrical drug-containing body 1e having the same base material as in Example 3 was used, and this was fitted to a cap-shaped protection member 9f without using a cylindrical heat conductive member. Then, the upper end of the drug-containing body 1e was heated by the ring-shaped heating element 12e to evaporate the insecticide. In the test, after the heating element 12e was energized, the amount of chemical vaporization at each heating time was quantitatively analyzed and measured in the same manner as in Example 2. The results are shown in Table 3.

[Table 3]

From the results shown in Table 3, in the case of Example 3 in which the drug-containing body was heated using the heat conductive member as shown in FIG. 8, the drug was stably evaporated over 360 hours. In Comparative Example 1 in which the conductive member was not used, stable transpiration was not obtained over a long period of time. This is because in the configuration shown in FIG. 8, since the drug-containing body is heated at a relatively uniform temperature, deterioration of the drug over time does not easily occur, the heated area is wide, and the drug inside the drug-containing body is large. It can be used for a long period of time because it requires a small transition distance. On the other hand, in the configuration shown in FIG. 12, the local heating by the heating element causes the decomposition of the drug over time in the upper part of the drug-containing body, and the clogging phenomenon occurs in the heated part of the drug-containing body. It is presumed that the drug contained in the lower part of the drug-containing body could not be transferred to the transpiration part in the upper part and remained contained. As described above, by heating the drug-containing body via the heat conductive member that matches the shape of the heating element, it becomes possible to stably and effectively evaporate the drug over a long period of time. Further, by using a heat conductive member having a different heat conductivity depending on the drug to be used, it is possible to evaporate various drugs without being limited to the temperature of the heating element.

[Brief description of drawings]

FIG. 1 is a schematic cross-sectional view showing a structural example of one mode of the method for heating and evaporating a drug of the present invention.

FIG. 2 is a schematic cross-sectional view showing a main part of another configuration example of the present invention.

FIG. 3 is a schematic cross-sectional view showing a main part of still another configuration example of the present invention.

FIG. 4 is a schematic cross-sectional view showing a structural example of another embodiment of the method for heating and evaporating a drug of the present invention.

FIG. 5 is a schematic cross-sectional view showing a structural example of still another embodiment of the method for heating and evaporating a drug of the present invention.

6 is a schematic cross-sectional view of a main part of the configuration example shown in FIG.

FIG. 7 is a schematic cross-sectional view showing another example of the shape of divided segments of the heat conductive member.

FIG. 8 is a schematic cross-sectional view showing a structural example of still another mode of the method for heating and evaporating a drug of the present invention.

FIG. 9 is a plan view showing a temperature measuring unit of each plate used in Example 1;

FIG. 10 is a graph showing the relationship between the measurement unit of each plate used in Example 1 and the measurement temperature.

FIG. 11 is a perspective view showing a heating form of a mosquito catching mat through each plate used in Example 2.

FIG. 12 is a schematic cross-sectional view showing a configuration of a heating evaporation device used in Comparative Example 1.

[Explanation of symbols]

1, 1a, 1b, 1c, 1d, 1e drug-containing body,
2,2a, 2b, 2c, 2d container, 3,3a, 3
b, 3c, 3d, 3e heat conductive member, 4 pedestal part,
5, 6 convex part, 8, 8a, 8b, 8d, 13, 1
4,24,34,35,47,48,49 vents,
9, 9a, 9c, 9d, 9e Protective member, 10, 10
a, 10b, 10c, 10d, 10e transpiration port, 1
1, 11c, 32, 40 heating evaporation device, 12, 12
b, 12c, 12d, 12e, 50 heating element, 25
a, 25b, 25a 'divided segment, 28 ring-shaped heat dissipation tube, 31 indicator functional member

Claims (5)

[Claims] 1. When heating a drug-containing body containing a drug with a heating element, a heat conductive member is provided between the drug-containing body and the heating element in contact with or in proximity to the heating element, and the drug-containing body is provided. A method for heating and evaporating a drug, which comprises heating by interposing a heat conductive member to evaporate the drug. 2. A heat-conductive member and / or another protective member substantially surrounds the periphery of the drug-containing body, and at the time of heating, at least partially around the surface of the drug-containing body from below and / or from the side. The heating and evaporation method according to claim 1, wherein a space communicating with the heat conductive member and / or the protection member is formed so that an upward heat flow is generated. 3. The heat evaporation method according to claim 2, wherein a drug evaporation port is provided at least at one position substantially above the drug containing body. 4. A heat conductive member is formed in a divided body, and each divided segment of the heat conductive member is movable so as to be pressed into contact with or contact with a heating element by elastic biasing force or gravity. The heating evaporation method according to any one of claims 1 to 3. 5. The heat evaporation method according to claim 4, wherein the heat conductive member is formed in a vertically divided cylindrical body.